Santos Wins Court Case Over Net Zero and Sustainability Claims 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Freedom Finance and Binance Join Forces in Digital Assets 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
